Description
What it is
A triple-receptor research compound activating GIP, GLP-1, and glucagon receptors simultaneously — currently the most-watched molecule in metabolic science.
Why it’s studied
GLP-3-RT extends the incretin research framework by adding glucagon receptor activity, which opens energy expenditure into the mechanism alongside the established incretin pathways. It’s the first triple agonist to reach mid-stage research and represents the leading edge of the category.
Key research findings
-
Most significant metabolic marker improvements ever recorded in the incretin class (Phase 2 research)
-
Documented improvements in HbA1c, lipid profile, and hepatic fat markers
-
Triple-receptor mechanism unique among research compounds in current development
